A warning signal for the risk of heart failure in patients with CML treated with BCR-ABL TKIs was suggested in 2006 by Kerkelä and colleagues when reporting a case series of 10 patients treated with imatinib that had developed heart failure with reduced LVEF. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.